Tyrosine kinase inhibitorPhase 3 trialInvestigational
Pazopanib
How it works
Blocks multiple signaling pathways that drive cancer cell growth, allowing the immune system to attack cancer cells.
Cancer types
Melanoma— All patients
Efficacy
Studies show that around 30% of patients achieved an objective response, with a median progression-free survival of approximately 4.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Ovarian Cancer Study Finds No Benefit in Adding Pazopanib to Paclitaxel | Ovarian Cancer | phase-2 | There was no difference between treatment arms in 4-month progression-free survival rate (61% with the combination versus 68% with paclitaxel alone). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.